Updates, announcements, and corporate developments from Huxley Health and AERASYN Biotech
Company engages capital partner for up to $15M financing and prepares for potential public listing amid growing U.S. policy and public discourse on psychedelics
A foundational capability supporting long-term pipeline expansion by addressing one of the industry's most critical structural challenges.
Ibogaine Synthesis & Manufacturing Infrastructure
Huxley Health, through its AERASYN Biotech division, is advancing one of a very limited number of synthesis and manufacturing-focused patent initiatives globally targeting ibogaine at scale. This work reflects an extended internal R&D effort and supports the company's belief that control over scalable supply infrastructure may become as important as clinical development itself as the sector matures.
Stay tuned for upcoming announcements, partnership developments, and corporate milestones as we continue to advance our mission.
Upcoming progress on our therapeutic programs and preclinical milestones.
New collaboration to expand our platform capabilities and reach.
Key achievements in our proprietary delivery and manufacturing systems.
Get notified when we release new updates, press releases, and corporate announcements.